» Articles » PMID: 27260018

The Association Between Clinician-based Common Terminology Criteria for Adverse Events (CTCAE) and Patient-reported Outcomes (PRO): a Systematic Review

Overview
Specialties Critical Care
Oncology
Date 2016 Jun 5
PMID 27260018
Citations 155
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials in cancer via the U.S. National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) for the purposes of ensuring patient safety. Recently, there has been a charge toward capturing the patient perspective for those AEs amenable to patient self-reporting via patient-reported outcomes (PRO). The aim of this review was to summarize the empirically reported association between analogous CTCAE and PRO ratings.

Methods: A systematic literature search was conducted using PubMed, EMBASE, Web of Science, and Cochrane databases through July 2015. From a total of 5658 articles retrieved, 28 studies met the inclusion criteria.

Results: Across studies, patients were of mixed cancer types, including anal, breast, cervical, chronic myeloid leukemia, endometrial, hematological, lung, ovarian, pelvic, pharyngeal, prostate, and rectal. Given this mixture, the AEs captured were variable, with many common across studies (e.g., dyspnea, fatigue, nausea, neuropathy, pain, vomiting), as well as several that were disease-specific (e.g., erectile dysfunction, hemoptysis). Overall, the quantified association between CTCAE and PRO ratings fell in the fair to moderate range and had a large variation across the majority of studies (n = 21).

Conclusions: The range of measures used and symptoms captured varied greatly across the reviewed studies. Regardless of concordance metric employed, reported agreement between CTCAE and PRO ratings was moderate at best. To assist with reconciliation and interpretation of these differences toward ultimately improving patient care, an important next step is to explore approaches to integrate PROs with clinician reporting of AEs.

Citing Articles

Efficacy of transarterial chemoembolization combined with radiofrequency ablation in the treatment of liver metastases from colorectal cancer.

Yin J, Zhao Y, Yin J, Yang S Clin Transl Oncol. 2025; .

PMID: 40042572 DOI: 10.1007/s12094-025-03879-0.


Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials.

Byrom B, Everhart A, Cordero P, Garratt C, Meyer T JMIR Cancer. 2025; 11:e64611.

PMID: 40020239 PMC: 11888580. DOI: 10.2196/64611.


A Cross-Sectional Survey of Oral Adverse Events and Oral Management Needs in Outpatients Receiving Cancer Drug Therapy.

Sakai Y, Katsura K, Kotake M, Toyama A Cancers (Basel). 2025; 17(4).

PMID: 40002235 PMC: 11853395. DOI: 10.3390/cancers17040641.


Relationships between patient-reported and clinician-rated toxicities and daily functioning in older adults with advanced cancer undergoing systemic therapy.

Culakova E, Mohamed M, Flannery M, Jensen-Battaglia M, Zhang Z, Ramsdale E Cancer. 2025; 131(4):e35766.

PMID: 39945245 PMC: 11822747. DOI: 10.1002/cncr.35766.


Pain detection using biometric information acquired by a wristwatch wearable device: a pilot study of spontaneous menstrual pain in healthy females.

Hirayama H, Yoshida S, Sasaki K, Yuda E, Yoshida Y, Miyashita M BMC Res Notes. 2025; 18(1):31.

PMID: 39849628 PMC: 11759418. DOI: 10.1186/s13104-025-07098-2.


References
1.
Vyzula R, Remick S . Lung cancer in patients with HIV-infection. Lung Cancer. 1996; 15(3):325-39. DOI: 10.1016/0169-5002(95)00596-x. View

2.
Tang B, Giuliani M, Le L, Higgins J, Bezjak A, Brade A . Capturing acute toxicity data during lung radiotherapy by using a patient-reported assessment tool. Clin Lung Cancer. 2012; 14(2):108-12. DOI: 10.1016/j.cllc.2012.06.003. View

3.
Downs S, Black N . The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998; 52(6):377-84. PMC: 1756728. DOI: 10.1136/jech.52.6.377. View

4.
Bennett B, Park S, Lin C, Friedlander M, Kiernan M, Goldstein D . Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer. 2012; 20(11):2959-67. DOI: 10.1007/s00520-012-1428-5. View

5.
Franklin H, Simonetti G, Dubbelman A, Ten Bokkel Huinink W, Taal B, Wigbout G . Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol. 1994; 5(2):113-7. DOI: 10.1093/oxfordjournals.annonc.a058760. View